Optimind Pharma Corp.
OMND
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.60% | -6.26% | -19.90% | -35.46% | -43.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.60% | -6.26% | -19.90% | -35.46% | -43.35% |
| Cost of Revenue | -7.28% | -25.31% | -61.57% | -64.22% | -60.28% |
| Gross Profit | 82.20% | 14.29% | 87.68% | 20.79% | 2.31% |
| SG&A Expenses | -62.83% | -60.51% | -39.98% | -44.31% | -51.73% |
| Depreciation & Amortization | -- | -- | -100.00% | -86.45% | -69.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -58.82% | -64.21% | -52.50% | -53.78% | -57.34% |
| Operating Income | 78.42% | 73.66% | 58.44% | 57.15% | 59.41% |
| Income Before Tax | 89.51% | 84.95% | 66.25% | 65.48% | 67.43% |
| Income Tax Expenses | -- | -- | -51.16% | -51.16% | -51.16% |
| Earnings from Continuing Operations | 89.42% | 84.85% | 66.51% | 65.72% | 67.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.42% | 84.85% | 66.51% | 65.72% | 67.64% |
| EBIT | 78.42% | 73.66% | 58.44% | 57.15% | 59.41% |
| EBITDA | -- | -- | 82.12% | 75.86% | 67.98% |
| EPS Basic | 88.61% | 85.44% | 68.47% | 67.73% | 71.58% |
| Normalized Basic EPS | 88.24% | 83.67% | 47.62% | 46.15% | 51.43% |
| EPS Diluted | 88.61% | 85.44% | 68.47% | 67.73% | 71.58% |
| Normalized Diluted EPS | 88.24% | 83.67% | 47.62% | 46.15% | 51.43% |
| Average Basic Shares Outstanding | 3.98% | 11.99% | 12.33% | 10.42% | 15.97% |
| Average Diluted Shares Outstanding | 3.98% | 11.99% | 12.33% | 10.42% | 15.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |